Gan & Lee Pharmaceuticals. (SHA:603087)
China flag China · Delayed Price · Currency is CNY
63.51
-0.59 (-0.92%)
Nov 17, 2026, 3:00 PM CST

SHA:603087 Balance Sheet

Millions CNY. Fiscal year is Jan - Dec.

Assets

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Equivalents
1,7302,088903.032,4432,8903,306
Short-Term Investments
191.16324.46--201.36276.44
Trading Asset Securities
2,5291,4011,5002,4101,6361,624
Cash & Short-Term Investments
4,4503,8142,4044,8534,7285,206
Cash Growth
40.56%58.68%-50.48%2.66%-9.20%14.24%
Accounts Receivable
936.59599.87251.81383.74189.57934.66
Other Receivables
7.3-0.168.291.630.990.16
Receivables
943.89599.71260.1385.37190.55934.82
Inventory
1,1921,0091,053860.51648.65651.33
Other Current Assets
124.6161.7874.3376.7397.3677.95
Total Current Assets
6,7115,4843,7916,1765,6646,870
Property, Plant & Equipment
3,6993,5773,8823,8863,6612,595
Long-Term Investments
303.831,3462,897304.6630201.36
Other Intangible Assets
606.68265.11273.06278.08293.48295.99
Long-Term Deferred Tax Assets
163.55213.67206.94168.95138.2530.8
Long-Term Deferred Charges
1,7841,611924.91821.97743.19588.87
Other Long-Term Assets
410.09129.0568.1379.9976.51270.33
Total Assets
13,67912,62712,04311,71510,60710,853

Liabilities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Accounts Payable
249.08126.21115.6194.8236.5226.15
Accrued Expenses
188.4295.26196.96192.54190173.04
Current Portion of Leases
-1.21.332.185.695.07
Current Income Taxes Payable
107.1314.531.491.421.35106.32
Current Unearned Revenue
32.7967.8863.2552.9968.1336.56
Other Current Liabilities
667.04310.69422.48429.49511.36138.39
Total Current Liabilities
1,244815.79801.13773.45813.04485.53
Long-Term Debt
228.08-----
Long-Term Leases
1.652.543.315.458.3312.17
Long-Term Unearned Revenue
211.33170.75168.92179.63187.63141.98
Long-Term Deferred Tax Liabilities
13.55-12.11--36.15
Other Long-Term Liabilities
2.689.52.971412.2710.2
Total Liabilities
1,702998.57988.45972.521,021686.02

Shareholders' Equity

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Common Stock
597.43597.3601.07594.16565.65561.54
Additional Paid-In Capital
3,5733,5343,5913,3512,5632,476
Retained Earnings
7,8677,6067,0596,8656,5257,133
Treasury Stock
-61.62-111.17-200.85-71.36-71.36-
Comprehensive Income & Other
1.243.064.043.823.44-3.44
Total Common Equity
11,97711,62811,05410,7439,58610,167
Minority Interest
---0-0.16-0.16
Shareholders' Equity
11,97711,62811,05410,7439,58610,167
Total Liabilities & Equity
13,67912,62712,04311,71510,60710,853

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Total Debt
229.733.744.647.6214.0117.24
Net Cash (Debt)
4,2213,8102,3994,8464,7145,189
Net Cash Growth
33.41%58.83%-50.49%2.80%-9.16%13.86%
Net Cash Per Share
7.136.434.068.558.379.25
Filing Date Shares Outstanding
591.31591.12598.96590.05561.54561.54
Total Common Shares Outstanding
591.31591.12598.96590.05561.54561.54
Working Capital
5,4674,6682,9905,4024,8516,385
Book Value Per Share
20.2619.6718.4618.2117.0718.11
Tangible Book Value
11,37011,36310,78110,4649,2929,871
Tangible Book Value Per Share
19.2319.2218.0017.7316.5517.58
Buildings
-2,1732,1371,3441,1651,046
Machinery
-2,2861,6011,4431,2371,263
Construction In Progress
-393.471,2622,0072,003874.91